Uncategorized

It’s time the Wizard gets his due

With Father’s Day coming up this Sunday it’s time we give the Wizard, Momma Kliff’s husband his due. Listen the guy just turned 95, no small accomplishment and while his musing may not get the ink Mom’s has the Wizard like Momma Kliff had a keen understanding of our wacky world even though he may not know it. Yes the Wizard and Momma Kliff were quite the pair and frankly...

A well-traveled path

As we watch investors boost shares of Livongo to what we believe are unsustainable levels we harken back to the past and remember other times when Diabetic Investor stood alone in the wilderness. This is not the first nor likely will it the last time when we went against the tide. The question is will be right about Livongo or will we eat crow. The first time this happened came after...

The Big Mo goes both ways

It’s not unusual for stocks in the diabetes sector to rise during ADA, even when this year ADA was a virtual event. ADA is one of the few times of the year when the sector receives a heightened amount of attention. Yet this heightened attention does not explain the incredible rise in Livongo. Over the past three months shares in the company have risen an astonishing 230%. Back on April...

Gamesmanship

According to Wikipedia - Gamesmanship is the use of dubious methods to win or gain a serious advantage in a game or sport. And nowhere is gamesmanship more prevalent than in the area of way cool whiz bang. Yes the toys in the toy chest continue to fascinate the folks in our wacky world no matter how many times we have to tell these people it’s not about the toys...

Upon further review

One of the more maddening things about football these days is the use of instant replay. Nothing is more irritating when your team scores a touchdown and the next thing you hear is “This play is under review”. Then for what seems like an eternity the officials and play by play broadcasters look at three hundred different camera angles trying to determine whether you should cheer all over or boo...

Consistent

One of the biggest issues when you have been around as long as we have it takes something truly astonishing to shock us. In the early days we were constantly amazed by all the wackiness that was going on. Now 20 plus years in we merely shrug our shoulders and chalk up the wackiness as one of the consistent aspects of our wacky world. No matter how much money is...

Well it took long enough, now what?

At a time when Medtronic is still promoting a CGM that requires fingerstick calibration, Abbott a leader in CGM technology got some long-awaited good news as finally at long last the FDA has approved the Libre2 and with an iCGM designation for good measure. Per a company issued press release; “Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM), announced today the U.S. Food and Drug Administration (FDA) cleared...

Why it’s over

We knew that when Sean Salmon took over the diabetes franchise that he’d be swimming upstream against the tide. The unit besieged by multiple issue was in serious need of overhaul and it was Mr. Salmon job to turn things around. Tandem and Insulet were forging ahead developing newer, better systems and were beginning to eat away at the company’s huge installed user base. Their CGM was a complete disaster...

A Head Scratcher

We have known for some time that Medtronic has been exploring multiple options for its struggling diabetes unit. Among the options being considered were a possible sale of the unit or combining the unit with another franchise and then spinning this combined entity off as separate publicly traded company. Our guess was a sale would involve private equity, the sticking point, excuse the expression would be how Medtronic valued the...

A small deal with a big message

Yesterday Novo Nordisk agreed to purchase Corvidia Therapeutics for $750 million in cash in a deal that could be worth $2.1 billion depending on regulatory and sales milestones achieved. This may not a blockbuster transaction, but it does send a loud message that Novo is beginning to expand beyond diabetes. As we have noted many times we cannot see Novo leaving diabetes as Sanofi seems to be doing. However Novo...